Healthcare Industry News: Allograft
News Release - March 22, 2006
Regeneration Technologies, Inc. Holds Launch of Sterling(R) Xenograft Line and BioSet(TM) DBM at AAOSALACHUA, Fla., March 22 (HSMN NewsFeed) -- Regeneration Technologies, Inc. (RTI) (Nasdaq: RTIX ), the Florida-based processor of orthopedic, cardiovascular and other biologic implants, is holding the official launch of its Sterling® xenograft line of implants as well as BioSet(TM) DBM at the American Association of Orthopaedic Surgeons (AAOS) annual meeting in Chicago this week.
"The official launch of these two new implant lines illustrates how Regeneration Technologies is once again leading the biologics evolution in health care," said Brian K. Hutchison, RTI chairman, president and CEO. "RTI remains committed to enhancing the lives of patients by pioneering health solutions through regenerative medicine."
The new Sterling product line, which includes the interference screws and cancellous chips and cubes, is available immediately through RTI's direct distribution representatives. Sterling Biological Matrix provides surgeons an expanded supply of safe, sterile tissue that is a natural alternative to autograft, Allograft and synthetic resorbable materials. Studies show that Sterling grafts maintain structural integrity and enhance biocompatibility.
In 2002, RTI sponsored an animal study of the effects of BioCleanse on xenograft tissue. The results showed that the BioCleanse treatment process renders bovine xenograft essentially equivalent to Allograft.
BioSet DBM consists of demineralized bone matrix (DBM) in a purified gelatin carrier, with bone chips added to the BioSet IC version. BioSet is available in various sizes and forms and is ideal for use as a bone void filler in many types of surgical procedures.
More information and demonstrations of both the Sterling and BioSet implants will be available at AAOS, booth 2141, or by contacting an RTI representative at (386) 418-8888.
About Regeneration Technologies, Inc.
RTI processes Allograft and xenograft tissue into shaped implants for use in orthopedic, cardiovascular and other surgeries with a commitment to science, safety and innovation.
RTI also holds the patents on BioCleanse®, the only proven tissue sterilization process validated to eliminate viruses, bacteria, fungi and spores from tissue without impacting the structural or biomechanical integrity of the tissue. The company has distributed more than 650,000 Allograft implants sterilized with the BioCleanse process with zero incidence of infection. RTI is accredited by the American Association of Tissue Banks and was named a 2004 Technology Pioneer by the World Economic Forum.
Except for historical information, any statements made in this press release about the company's anticipated financial results, future operational results, regulatory approvals or changes to the company's agreements with its distributors are forward-looking statements subject to risks and uncertainties, such as those described in the company's public filings on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results reflected in these forward-looking statements. Copies of the company's SEC filings may be obtained by contacting the company or the SEC or by visiting RTI's web site at http://www.rtix.com or the SEC's web site at http://www.sec.gov .
Source: Regeneration Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.